Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Request metadata listed "Altimmune, Inc.", but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. The company has no commercial products and relies on U.S. government contracts and grants for revenue. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), Protexia (nerve agent countermeasure), and RypVax (plague vaccine).
Recent Acquisition: In April 2008, the company acquired the biodefense vaccines business of Avecia Biologics Limited, adding SparVax and RypVax to its portfolio.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenue | $32.9 million | $14.6 million |
| Net Loss | $(36.4) million | $(13.6) million |
| Operating Loss | $(35.2) million | $(16.5) million |
| Research & Development Expenses | $31.8 million | $16.6 million |
| General & Administrative Expenses | $19.4 million | $13.9 million |
| Cash and Cash Equivalents (Year End) | $19.8 million | $40.6 million |
| Restricted Cash | $13.3 million | $0 |
| Short-Term Investments | $3.2 million | $12.2 million |
| Convertible Notes (Debt) | $13.4 million | $0 |
| Long-Term Debt | $0.9 million | $16.7 million |
| Accumulated Deficit | $(123.8) million | $(87.4) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 125% to $32.9 million, driven primarily by the acquisition of Avecia assets in Q2 2008, which contributed $11.9 million in revenue from government contracts for SparVax and RypVax.
- Expense Increase: Operating expenses rose significantly to $68.2 million (from $31.1 million in 2007). This includes a one-time charge of $16.1 million for acquired in-process research and development (IPR&D) related to the Avecia acquisition.
- Cash Position: Cash and cash equivalents decreased by $20.8 million to $19.8 million. This decline was due to the $10 million cash payment and $7 million letter of credit funding for the Avecia acquisition, increased operating costs, and debt repayments, partially offset by a $13.1 million equity investment from Panacea Biotec in October 2008.
- Debt Structure: The company restructured its debt, converting bridge notes into $12.3 million of 8% convertible notes (current liability) and maintaining a $10 million credit facility with $5 million outstanding.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company has incurred cumulative losses and expects to continue doing so. Management states that continuation as a going concern is dependent on obtaining adequate financing and government funding. Without additional funding, the company may need to identify financing within the next 12 months.
- Government Contract Dependence: The company is heavily reliant on U.S. government contracts (DoD, NIAID, BARDA). Risks include the government's ability to unilaterally terminate contracts, reduce scope, or delay spending due to economic conditions.
- Key Contract Milestones:
- SparVax: Awaiting award decision on RFP-BARDA-08-15 for 25 million doses of anthrax vaccine. Failure to receive this award could force significant curtailment of operations.
- Protexia: DoD contract provides $41 million initial funding; potential for additional $65 million and up to $219 million total if milestones are met and procurement options are exercised.
- Valortim: $13.9 million contract with NIAID/BARDA; BARDA indicated potential for an additional $2 million.
- Regulatory Risks: Products rely on the FDA "Animal Rule" for approval, as human efficacy trials for bioweapons are unethical. Success in animal models does not guarantee FDA approval.
- Subsequent Events: In March 2009, the company completed a public offering raising approximately $5.5 million. Additionally, lenders agreed to reduce restricted cash requirements from 1.25x to 0.5x outstanding obligations.
Investor Verification Checklist
- Contract Award Status: Verify the status of the RFP-BARDA-08-15 award for SparVax, as the company's future viability is heavily tied to this specific contract.
- Cash Runway: Assess the company's ability to fund operations through 2009 given the $19.8 million cash balance and ongoing negative cash flow, considering the recent $5.5 million capital raise.
- Debt Obligations: Review the terms of the $13.4 million convertible notes (due August 2009) and the $5 million credit facility to understand refinancing or conversion risks.
- Acquisition Milestones: Monitor potential milestone payments to Avecia (up to $23 million) and royalty obligations triggered by future government contracts or sales.
- Regulatory Pathway: Confirm progress on Phase I clinical trials for Protexia and the status of animal efficacy studies required for FDA licensure under the Animal Rule.